Check for updates

OPEN ACCESS

EDITED BY Monica Baiula, University of Bologna, Italy

REVIEWED BY Pabitra Bikash Pal, University of Pittsburgh, United States Dino Bekric, Paracelsus Medical University, Austria

*CORRESPONDENCE Wenhao Ren, herohao@163.com Keqian Zhi, zhikeqian@sina.com

† These authors have contributed equally to this work

RECEIVED 14 May 2024 ACCEPTED 18 July 2024 PUBLISHED 07 August 2024

CITATION

Sun K, Gao L, Li S, Zheng J, Zhu Z, Zhi K and Ren W (2024), Circ-CDK8 regulates SLC7A11 mediated ferroptosis by inhibiting miR-615-5p to promote progression in oral squamous cell carcinomas. Front. Pharmacol. 15:1432520.

doi: [10.3389/fphar.2024.1432520](https://doi.org/10.3389/fphar.2024.1432520)

COPYRIGHT

© 2024 Sun, Gao, Li, Zheng, Zhu, Zhi and Ren. This is an open-access article distributed under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) [License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

[Circ-CDK8 regulates](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full) [SLC7A11-mediated ferroptosis by](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full) [inhibiting miR-615-5p to promote](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full) [progression in oral squamous cell](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full) [carcinomas](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full)

Kai Sun^{1,2,3†}, Ling Gao^{1,2,3,4†}, Shaoming Li^{1,2,3†}, Jingjing Zheng⁵, Zhuang Zhu^{1,2,3}, Keqian Zhi^{1,2,3,4*} and Wenhao Ren^{1,3*}

¹Department of Oral and Maxillofacial Reconstruction, The Affiliated Hospital of Qingdao University, Qingdao, China, ²School of Stomatology, Qingdao University, Qingdao, China, ³Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China, ⁴Key Lab of Oral Clinical Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China, ⁵Department of Endodontics, The Affiliated Hospital of Qingdao University, Qingdao, China

Introduction: Ferroptosis is a new mode of programmed cell death distinct from necrosis, apoptosis, and autophagy, induced by iron-ion-dependent lipid peroxide accumulation. Circular RNAs are a class of endogenous non-coding RNAs that regulate the biological behavior of tumors. However, the role of circ-CDK8 in regulating ferroptosis, migration, and invasion of oral squamous cell carcinoma (OSCC) remains unknown.

Methods: The effect of circ-CDK8 on OSCC cell ferroptosis, migration, and invasion was evaluated using CCK-8, wound healing, transwell, reactive oxygen species (ROS), malondialdehyde (MDA), and GSH assays and Western blotting. Bioinformatics analyses and luciferase reporter assays were performed and revealed targeted relationships between circ-CDK8 and miR-615-5p, miR-615-5p and SLC7A11. Interference with circ-CDK8 expression reduced SLC7A11 expression by sponging miR-615-5p, suppressed OSCC cell migration and invasion, and promoted ferroptosis by increasing ROS, MDA, and iron levels and decreasing GSH and GPX4 levels in OSCC cells. Furthermore, in vivo, animal experiments confirmed that circ-CDK8 interference inhibited OSCC cell proliferation and SLC7A11 expression.

Results: Collectively, this study revealed a novel strategy to upregulate erastininduced ferroptosis in OSCC cells via the circ-CDK8/miR-615-5p/SLC7A11 axis, providing new insights into OSCC and a potential therapeutic strategy for OSCC.

KEYWORDS

oral squamous cell carcinoma, circ-CDK8, SLC7A11, ferroptosis, migration, invasion

Introduction

Oral squamous cell carcinoma (OSCC) is the most common head and neck malignant tumor ([Duprez et al., 2017](#page-10-0)). It is characterized by high morbidity and mortality, with 1,958,310 new cases and 609,820 deaths in the United States [\(Siegel et al., 2023](#page-10-1)). Despite recent advances, the treatment of OSCC is still based on a combination of surgery, followed by radiotherapy, chemotherapy, and immunotherapy, with a 5-year survival rate of approximately 40%–60% [\(Mody et al., 2021\)](#page-10-2). However, patients who cannot tolerate surgery and have high facial appearance requirements cannot benefit from this treatment [\(Ringash, 2015](#page-10-3)), and the side effects, poor clinical response, and other problems related to radiotherapy and chemotherapy affect their clinical application [\(Meric-Bernstam et al.,](#page-10-4) [2021\)](#page-10-4). Therefore, identifying the potential carcinogenic mechanism of OSCC and specific therapeutic targets for OSCC is warranted.

Circular RNAs (circRNAs) are a class of endogenous non-coding RNAs that produce covalent closed-loop structures by back splicing. They have been shown to regulate the biological behavior of tumors ([Li et al., 2020b](#page-10-5); [Chen, 2020;](#page-10-6) [Zhao et al., 2020](#page-11-0); [Zheng et al., 2022;](#page-11-1) [Cui](#page-10-7) [et al., 2023\)](#page-10-7). Thus, in our previous study, we used circRNA microarrays to screen for differential circRNA expression profiles in paired OSCC and normal tissues and found a clinically significant downregulation of the circRNA circ-PKD2 and an upregulation of the circRNA circ-CDK8 [\(Gao et al., 2019\)](#page-10-8). The study showed that circ-PKD2 can promote autophagy by targeting miR-646, which promotes the sensitivity of OSCC cells to cisplatin chemotherapy ([Gao et al.,](#page-10-8) [2019](#page-10-8); [Gao et al., 2022\)](#page-10-9). Therefore, we intend to explore the regulatory mechanism of circ-CDK8 in OSCC.

In 2012, ferroptosis was reported as a novel form of iron-dependent cell death [\(Dixon et al., 2012\)](#page-10-10). It was primarily categorized into two pathways: endogenous and exogenous [\(Li et al., 2020a](#page-10-11)). The exogenous route is mainly concerned with the inhibition of the glutamate/cystine antiporter system (system Xc[−]), as well as the activation of iron transporters such as serotransferrin and lactotransferrin [\(Chen et al.,](#page-10-12) [2021\)](#page-10-12). The endogenous pathway involves the suppression of the biosynthesis of the intracellular antioxidant enzyme, glutathione peroxidase 4 (GPX4). Drugs like Erastin and RSL3 induce ferroptosis in RAS-deficient cells via these endogenous and exogenous pathways, respectively [\(Yang and Stockwell, 2008\)](#page-11-2). The main characteristics of ferroptosis include the accumulation of lipid peroxides, muscle building of reactive oxygen species (ROS), and the accumulation of iron ions ([Liang et al., 2019](#page-10-13); [Chen et al., 2021](#page-10-12)). Cell ultrastructure showed that ferroptosis with mitochondrial atrophy, shrinkage or disappearance of mitochondrial ridges, increased membrane density, and normal nuclear morphology but lack of chromatin agglutination ([Gan, 2021](#page-10-14); [Tan et al., 2022](#page-11-3)).

Increased intracellular oxygen elevates the levels of harmful products, particularly reactive oxygen species (ROS), triggering cell death [\(Conrad and Pratt, 2019](#page-10-15)). Research has indicated that GPX4 and ferroptosis suppressor protein 1 (FSP1) inhibited the accumulation of ROS and the progression of ferroptosis. Consequently, the occurrence of ferroptosis is influenced by three key pathways: (1) the system Xc^{-/} GPX4-related pathway, (2) the FSP1-related pathway, and (3) the iron metabolism pathway. Targeting ferroptosis associated pathways in cancer cells can be an effective strategy for cancer therapy. For example, Shen et al. found that Poly (rC)-binding Protein 2 (PCBP2), an RNA-binding protein, could bind and stabilize the expression of SLC7A11 mRNA, which inhibiting tumor ferroptosis and promoting tumor progression in bladder cancer [\(Shen et al., 2022\)](#page-10-16). Sun et al. demonstrated that NF-kB activating protein (NKAP) protected glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m⁶A-dependent manner [\(Sun K.](#page-10-17) [et al., 2022](#page-10-17)). We previously demonstrated that SLC7A11 is a key protein that regulates ferroptosis ([Sun S. et al., 2022\)](#page-11-4). Besides, as an inducer of iron death sorafenib and sulfasalazine have been widely used

in the targeted therapy of clinical cancer ([Chen et al., 2021\)](#page-10-12). So ferroptosis will be an interesting option for studies. Additionally, we found that circ-CDK8 was upregulated in OSCC cells and tissues. To further assess the interaction between circ-CDK8 and SLC7A11, we analyzed the starBase v2.0 and TargetScan databases and found that miR-615-5p served as a bridge. Therefore, this study aims to confirm that circ-CDK8 regulates the biological behavior of OSCC via ferroptosis.

In this study, the expression of circ-CDK8 in 43 pairs of OSCC tissues and paired normal tissues was analyzed. We found that circ-CDK8 was highly expressed in OSCC tissues. We report for the first time that circ-CDK8 regulates ferroptosis through the miR-615-5p/ SLC7A11 axis. Further functional experimental further demonstrated that downregulation of circ-CDK8 transcription inhibited the proliferation, migration and invasion of OSCC cells. Therefore, this study provides a new potential therapeutic target for OSCC treatment.

Materials and methods

Cell culture and transfection

Cell lines SCC-25, CAL-27, and HOK were purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Science (Shanghai, China). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Pricella, China) supplanted with 10% fetal bovine serum (FBS, HyClone, United States) and a mixture of 1% penicillin-streptomycin (Pricella, China) at 37°C under 5% CO₂ atmosphere.

Si-circ-CDK8, miR-615-5p inhibitor, si-SLC7A11, and negative control (NC) plasmid were purchased from GenePharma (Shanghai, China). The cells were inoculated in a six-well plate and transfected with Lipofectamine 3,000 (Thermo Fisher Scienticic) when the cell density reached 60%.

Ferrostain-1 (Selleck, S7243), a potent and selective ferroptosis inhibitor, Z-VAD-FMK (Selleck, S7023), a cell permeable, irreversible caspase inhibitor, and Necrosulfonamide, a specific and effective inhibitor of cell necrosis were purchased from Selleck (Shanghai, China). And their working concertation according to the manufacturer's instructions.

RNA extraction and quantitative real-time PCR (qRT-PCR)

Total RNA extraction and reverse transcription were performed using trizol (Thermo Fisher Scientific) and Prime Script RT kits (Takara, Japan) according to the instructions. qRT-PCR was performed using SYBR GREEN PCR Master Mix (Takara, Japan). The relative levels of miRNA and circRNA were calculated using the $2^{(-\Delta \Delta \text{Ct})}$ formulae. All the primers used in the study are shown in [Table 1.](#page-2-0)

Western blotting analysis

Total proteins were extracted from SCC-25 or CAL-27 cells using RIPA lysis buffer (Beyotime Biotechnology, China). The

TABLE 1 Primer sequences.

protein concentration was measured using the BCA protein assay kit (Solarbio, China) according to the manufacturer's instructions. Equal amounts of proteins were separated in 8%–12% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene fluoride membranes (PVDF). The membranes were blocked with 5% skim milk powder in PBST at room temperature for 2 h before overnight incubation at 4° C with the primary antibody. After three washes with PBS, the PVDF membrane was incubated with the secondary antibody for 2 h at room temperature. Finally, protein bands were visualized using the ChemiDoc Touch Imaging System (Biorad). The following antibodies were used in the Western blotting process: anti-GPX4 (1:1000, Abcam, cat.no.ab125066), SLC7A11 (1:1000, Abcam, cat.no.ab125066), GAPDH (1:2000, Elabscience, cat.no.E-AB-20059), and anti-Rabbit IgG (1:10,000, Proteintech, cat. no.10285-1-AP).

Immunohistochemical (IHC) analysis

Oral tissues were sliced into thin (3–6 μm) sections, sequentially dewaxed with xylene and anhydrous ethanol, and then treated with citric acid antigen repair solution at high temperature. The tissue sections were then incubated overnight at 4° C with primary antibody diluted with PBS (1: 100) and thereafter with DAB on and hematoxylin dye at room temperature. Finally, the tissue sections were dehydrated, and images were acquired using Olympus BX53 microscope (Olympus, Tokyo, Japan).

Cell viability assay

Cell viability was used to measure the proliferation rates of cells. Here, 100 ul of treated cells were inoculated and cultured in 96-well plates for 24 h, and the proliferation rate of cells was detected using the Cell Counting Kit (CCK-8, Solarbio, China). The OD value was recorded at 450 nm by a microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, United States).

Cell death analysis

Treated cells (1×10^6) were washed with PBS and resuspended in 100 μL 1 × Annexin V Binding Buffer. Annexin V (2.5 μL) and PI (2.5 μL) (Solarbio, China) were added to the cell suspension and incubated at room temperature for 15 min in darkness. Finally, $1 \times$ Annexin V was added to the cell suspension to achieve a final volume of 500 μL before analysis with flow cytometry (Bechman Coulter, Palo, Alto, CA, United States).

Luciferase reporter assay

Cells were transfected with wild-type (WT) or mutated (MUT) circ-CDK8 3′UTR reporter plasmid with miR-615-5p mimics or negative controls using Lipofectamine 3,000 according to the manufacturer's instructions. After 48 h transfection, firefly and Renilla luciferase activities were measured consecutively using the Dual-Luciferase Reporter Assay System (Promega, United States).

Wound healing and transwell assays

Cells were inoculated in six-well plates and treated differently. When the cell density reached 95% confluence, a scratch was made using a 200 ul gun tip. The cells were washed three times with PBS, and the culture medium without FBS was replaced. The cells were placed in the incubator and observed after 12 h and 24 h. The cells were digested, re-suspended in an FBS-free medium, and counted, and 1×10^5 cells were added to the upper layer of the transwell chamber, which was placed in a 24 well plate. FBS-containing medium (600ul) was added to the lower layer. Cells that had migrated to the lower chamber after 24 h and 48 h were gently scrapped, fixed in 4% paraformaldehyde for 30 min, stained with 0.1% crystal violet for 30 min, washed with running water, and observed under a microscope.

Transmission electron microscopy (TEM)

The SCC-25 and CAL-27 cells were harvested and fixed in the 2.5% Glutaraldehyde (Solarbio, China). The cells were then observed and photographed with a transmission electron microscope (JEM-1200, Jeol, Japan).

Detection of intracellular ROS, MDA, and GSH

SCC-25 and CAL-27 cells were specially treated and inoculated onto cell culture plates. The level of ROS was determined using 2′7′ dichlorodihydrofluorescein diacetate (DCFH-DA), while malondialdehyde (MDA) and GSH levels were determined using respective kits (Beyotime Biotechnology).

In vivo nude mice model

The protocols for animal experiments were approved by the Animal Care and Use Committee of the Affiliated Hospital of Qingdao University (AHQU-MAL20210604). Four-week-old female nude mice were purchased from the Charles River (Beijing, China). The animal experiments were conducted at the Affiliated Hospital of Qingdao University animals' Laboratory. The mice were injected subcutaneously with sh-NC or sh-circ-CDK8 CAL-27 cells (5×10^{-6}) in 100 ul PBS. When the tumors reached about 80 mm³, the mice were injected intraperitoneally with 5 mg/kg erastin every 2 days eight times. The tumor size was analyzed every 5 days.

Statistical analysis

Data were analyzed using GraphPad Prism 8. Differences between groups were analyzed using t-test. Continuous normally distributed data were expressed as mean \pm SEM. *p < 0.05, **p < 0.01 were considered statistically significant.

Results

The expression of circ-CDK8 was higher in OSCC

Based on the findings of a previous study on circRNA ([Gao,](#page-10-8) [Zhao, Li, Dou, Wang, Liu, Ren and Zhi, 2019](#page-10-8)), we first evaluated the expression of circ-CDK8 in 43 OSCC tumor tissues and matched normal samples. We found that circ-CDK8 levels were significantly higher in OSCC tissues compared with the normal tissues ([Figure 1A\)](#page-4-0). We further investigated the clinicopathologic characteristics of OSCC patients and found that the expression of circ-CDK8 positively correlated with tumor size, lymph node metastasis and histological grade ([Table 2](#page-4-1)). Accordingly, Kaplan-Meier analysis revealed that patients with higher circ-CDK8 levels had a poorer prognosis than those with lower expression ([Figure 1C\)](#page-4-0). Similarly, the expression of circ-CDK8 was higher in OSCC cells (SCC-25 and CAL-27) than in the human oral keratinocyte (HOK) ([Figure 1B\)](#page-4-0). These results showed that the expression of circ-CDK8 was different between OSCC and normal tissues. Thus, the distinct biological and clinical behaviours of OSCC cells may be implicated to circ-CDK8.

Circ-CDK8 regulated the biological behavior of OSCC cells

Since the biogenesis, function, and clinical significance of circRNA have been extensively studied ([Li et al., 2020a](#page-10-11)), we further explored whether circ-CDK8 regulates the biological behavior of OSCC cells. We found that low circ-CDK8 levels significantly decreased the proliferation of SCC-25 and CAL-27 cells ([Figure 2A\)](#page-5-0). Moreover, the rate of cell death was significantly higher in the circ-CDK8 interference group than in the control group ([Figure 2B\)](#page-5-0). Reducing the circ-CDK8 level slowed down the migration of OSCC cells significantly ([Figure 2C\)](#page-5-0). Similarly, we found that the migration and invasion of cells was significantly lower in the circ-CDK8 interference group ([Figure 2D\)](#page-5-0). Generally, circ-CDK8 was highly expressed in oral squamous carcinoma tissues and interfering with circ-CDK8 transcription significantly inhibited cell proliferation, migration and invasion of OSCC cell lines.

MiR-615-5p and SLC7A11 are downstream genes regulated by circ-CDK8

The downstream targets of circ-CDK8 were identified using bioinformatics analyses using data in the Starbase v2.0 database. The results showed that let-7a-5p, let-7b-5p, let-7c-5p miR-98-5p, miR-202-3p, miR-615-5p, miR-19a-3p could be downstream targets of circ-CDK8. qRT-PCR analyses further revealed that overexpression of circ-CDK8 significantly reduced the expression of let-7b-5p and miR-615-5p [\(Supplementary Figure S1\)](#page-10-18). Thus, miR-615-5p expression was analyzed in the subsequent experiments. Previous studies have shown that circRNAs function by sponging miRNAs([Hong et al., 2020\)](#page-10-19). Firstly, we found circ-CDK8 and miR-615-5p gene targets ([Figure 3A\)](#page-6-0). Further analysis revealed that interference with circ-CDK8 in both SCC-25 and CAL-27

 $*_{p<} 0.05$

cell lines ([Figure 3B](#page-6-0)). To further confirm the correlation between circ-CDK8 and miR-615-5p expression, miR-615-5p mimics was co-transfected in the SCC-25 cells with circ-CDK8 wild type (WT) or mutated (MUT) circ-PKD2 [\(Figure 3C\)](#page-6-0). These results suggested that circ-CDK8 acted as a miR-615-5p sponge in OSCC. Then we searched for downstream miR-615-5p target genes through the TargetScan database and found that miR-615-5p targets SLC7A11 ([Figure 3D\)](#page-6-0). We analyzed the expression of SLC7A11 in various tumors through Timer database ([https://](https://cistrome.shinyapps.io/timer/) cistrome.shinyapps.io/timer/), and results showed that SLC7A11 expression was significantly difference in head and neck squamous cell carcinoma (HNSC) ([Supplementary Figure](#page-10-18) [S3](#page-10-18)). In addition, we downloaded phenotypic data of head and neck squamous cell carcinoma (HNSCC) from the TCGA website. We preliminarily analyzed the expression level of SLC7A11 and clinicopathological indicators, and found that the expression of SLC7A11 was related to gender [\(Supplementary Table S4\)](#page-10-18). Immunohistochemical results showed that compared with the normal tissues, SLC7A11 was highly expressed in tumour tissues ([Figure 3E](#page-6-0)). Western blot and qRT-PCR revealed similar results ([Figures 3F, G\)](#page-6-0). QRT-PCR and Western blot were performed to confirm the regulatory relationship between circ-CDK8 and SLC7A11. The results showed that interference with circ-CDK8 significantly reduced SLC7A11 expression at both mRNA and protein levels ([Figures 3H, I](#page-6-0)). Since SLC7A11 is a critical regulator of ferroptosis ([Lang et al., 2019](#page-10-20)), we speculated that circ-CDK8 regulated ferroptosis. In the present study, ferroptosis was induced using erastin. Results showed that erastin treatment reduced the viability of both SCC-25 and CAL-27 had reduced cell viability under Erastin treatment, suggesting that OSCC cells are sensitive to ferroptosis ([Figure 3J\)](#page-6-0). Importantly, interfering with circ-CDK8 in Erastin-treated SCC-25 and CAL-27 cells still reduced cell viability [\(Figure 3K](#page-6-0)), suggesting a link between circ-CDK8 and

ferroptosis. Generally, our results showed that circ-CDK8 regulates miR-615-5p transcription and translation, and it plays an important role in OSCC cells' ferroptosis.

Circ-CDK8 regulates ferroptosis of OSCC cells

Because circ-CDK8 has been linked to ferroptosis, we investigated the mechanism by which circ-CDK8 regulates ferroptosis. Previous studies have shown that GPX4 is a key negative regulatory enzyme for the onset of ferroptosis and that GPX4 deficiency leads to lipid peroxidation and ferroptosis. In addition, a significantly low GSH level was associated with GPX4 deficiency and ROS accumulation ([Yang et al., 2014](#page-11-5)). Interestingly, our results showed that miR-615-5p knockdown increased the expression of GSH and GPX4 by reducing the inhibition of ferroptosis by circ-CDK8 under erastin treatment ([Figures 4A, B\)](#page-7-0). Similarly, circ-CDK8 significantly increased the levels of active iron, but this effect was attenuated by miR-615-5p ([Figure 4C](#page-7-0)). In addition, reactive oxygen (ROS), lipid peroxides and malondialdehyde (MDA) were higher in the si-circ-CDK8 group than in the miR-615-3p inhibitor group ([Figure 4D,](#page-7-0) [Supplementary Figure S2](#page-10-18); [Figure 4E](#page-7-0)). Moreover, mitochondrial swelling and mitochondrial cristae reduction or disappearance were observed in the circ-CDK8 interference group. However, miR-615-5p inhibition reversed this phenomenon ([Figure 4F\)](#page-7-0). Overall, circ-CDK8 regulated ferroptosis by sponging miR-615-5p and inhibiting the ability of SLC7A11, and mitochondria played a critical role in the ferroptosis of OSCC cells.

Circ-CDK8 impacted the biological behavior of OSCC cells by regulating SLC7A11 expression

As a member of the glutamate/cystine reverse transport system (system Xc-), SLC7A11 suppresses the development/progression of several cancers [\(He et al., 2023](#page-10-21); [Xu et al., 2023](#page-11-6)). In the study, modulating SLC7A11 expression reduced the migration and invasion ability of SCC-25 and CAL-27 cells. Interestingly, cotransfection with miR-615-5p inhibitor and si-SLC7A11 augmented the inhibition of the migration and invasion ability of SCC-25 and CAL-27 cells ([Figure 5A\)](#page-8-0). Similarly, interfering with the circ-CDK8 induced the cell death of SCC-25 and CAL-27, and cotransfection with miR-615-5p inhibitor increased the rate of cell death ([Figure 5B\)](#page-8-0). Interestingly, we found that only ferroptosis inhibitors (Ferropstain-1, DFO) reversed the reduction in cell viability induced by Erastin, whereas apoptosis and necrosis inhibitors did not [\(Figure 5C](#page-8-0)). Based on the above results, SLC7A11 plays an important role in the migration and invasion of OSCC cells by inhibiting ferroptosis, and circ-CDK8 acts via the miR-615-5p pathway.

Circ-CDK8 regulated OSCC cell growth in vivo

To further explore whether circ-CDK8 regulates cancer cell growth in vivo, SCC-25 cells transfected with sh-circ-CDK8 or negative control were subcutaneously injected into nude mice. We found that the volume and weight of the SCC-25 xenograft decreased in the shcirc-CDK8 group [\(Figures 6A](#page-9-0)–[C\)](#page-9-0). The expression of miR-615-5p was upregulated in sh-circ-CDK8 groups [\(Figure 6D\)](#page-9-0). Immunohistochemistry (IHC) staining showed that the expression of SLC7A11 was lower in the sh-circ-CDK8 group [\(Figure 6E\)](#page-9-0). These in vivo results further confirmed that interfering with circ-CDK8 inhibits the OSCC proliferation.

Discussion

OSCC is the most prevalent oral malignancy. Currently, OSCC is mainly treated by surgery, supplemented with

radiotherapy. With the continuous progress in diagnostic imaging technology, surgical methods, radiotherapy and other adjuvant treatments, as well as systemic treatments, the mortality rate of oral cancer has been decreasing. However, the 5-year survival rate of patients with squamous cell carcinoma of the oral cavity is only about 40%–60% ([Mody, Rocco, Yom, Haddad and](#page-10-2) [Saba, 2021](#page-10-2)). Recent studies have focused on the pathogenesis and markers of OSCC. The present study demonstrated that circ-CDK8 promotes the SLC7A11 expression by competitive sponging of miR-615-5p to prevent the ferroptosis of OSCC cells [\(Figure 7\)](#page-9-1).

Accumulating evidence has shown that abnormal expression circRNAs play a critical role in cancer development ([Bose and](#page-10-22) [Ain, 2018](#page-10-22); [Li et al., 2023;](#page-10-23) [Zhang et al., 2023\)](#page-11-7). In the study, circRNA microarrays revealed that circ-CDK8 is over-expressed in OSCC cells. Prior to this study, the role of circ-CDK8 in cancer cells had not been reported. We found that circ-CDK8 expression was significantly higher in cancer tissues and OSCC cells than in normal tissue and HOK cells. The expression level

of circ-CDK8 is tightly associated with clinical characteristics, such as TNM stage, histological grade, tumor size and postoperative survival rate of OSCC patients. Interfering with circ-CDK8 transcription/function significantly reduced the viability and migration of OSCC cells in vivo and in vitro ([Figures 2A,](#page-5-0) [6A\)](#page-9-0). Our findings revealed that circ-CDK8 is a critical tumor-promoting factor, and it regulates protein expression by modulating RNA-protein interactions or through RNA splicing.

To clarify the specific mechanism by which circ-CDK8 regulates OSCC progression, we predicted the possible gene targets of circ-CDK8 through bioinformatics analysis. We found that circ-CDK8 possibly targets let-7a-5p, let-7b-5p, let-7c-5p miR-98-5p, miR-202- 3p, miR-615-5p, and miR-19a-3p. Studies [\(Wu M. et al., 2021](#page-11-8); [Zeng](#page-11-9) [et al., 2021](#page-11-9)) have shown that the expression of miR-615-5p in OSCC cells is associated with the circ- CDK8. In our study, we found that interfering with miR-615-5p transcription/function can effectively abrogate the inhibition of cell migration invasion due to interference with circ-CDK8 function ([Figure 5A\)](#page-8-0). Our results demonstrated that miR-615-5p was a direct downstream target of circ-CDK8, and miR-

615-5p effectively inhibited the migration and invasion of OSCC cells.

Further analysis of data in the TargetScan database revealed that SLC7A11 targets miR-615-5p. The main role of SLC7A11 is to mediate the transmembrane exchange of cystine and glutamate, which involves both the regulation of extracellular glutamate concentration and the provision of raw material for intracellular GSH synthesis ([Lin et al., 2020;](#page-10-24) [Yuan et al., 2021](#page-11-10)). GSH and GPX4 are active substances that inhibit the production of ROS in cells. In this study, we found that circ-CDK8 increased the expression of GSH and GPX4 by competitive sponging miR-615- 5p. Meanwhile, inhibited the migration of SLC7A11 cells. Our study also confirmed that circ-CDK8 effectively decreases ROS production and promotes lipid peroxide accumulation, inhibiting the ferroptosis of OSCC cells. Whether circ-CDK8 affects the migration and invasion of OSCC cells by regulating ferroptosis was explored further.

Ferroptosis is a new type of regulated cell death, which differs from apoptosis and necrosis and is characterized by the accumulation of iron-dependent lipid peroxidation [\(Dixon](#page-10-10)

OSCC transfected with si-circ-CDK8, miR-615-5p inhibitor and/or si-SLC7A11 under the Erastin. Scar bar = 100 μm. (B) Flow cytometry showed that cell death rate in different. (C) Cell viability of SCC-25 cells following treatment with ferrostain-1 (0.5uM), deferoxamine (DFO, 100 µM) or Z-VAD-FMK (20uM) for 12 h.

[et al., 2012\)](#page-10-10). As the molecular and physiological mechanisms of ferroptosis continue to be elucidated, the strategy of circRNAs to treat tumors through ferroptosis has gained widespread support. For example, circRAPGEF5 medicated ferroptosis by modulating alternative splicing of TFRC in endometrial cancer, and circRAPGEF5/RBFOX2 axis might be a cancer therapy target ([Zhang et al., 2022](#page-11-11)). CircEPSTI1 promotes cells progression by miR-375/409-3P/515-5p-SLC7A11 axis in cervical cancer ([Wu P.](#page-11-12) [et al., 2021\)](#page-11-12). In the present study, we found that interfering with circ-CDK8 function decreased the expression of SLC7A11 and promoted the accumulation of MDA (end product of lipid peroxidation) and ROS under the treatment of si-circ-CDK8, inhibiting the migration and invasion of OSCC. Erastin, a laboratory ferroptosis inducer, produced significant inhibition of OSCC, that suggested that OSCC are sensitive to ferroptosis.

Ferroptosis-related clinical chemotherapeutic agents such as sorafenib and sulfasalazine may play an important role in OSCC treatment. Our findings further revealed that circ-CDK8 increased the expression of SLC7A11, GSH and GPX4, which decreased the intracellular MDA and ROS levels. Additionally, circ-CDK8 decreased ferroptosis but increased the migration and invasion of OSCC cells. The current study shows, for the first time, that si-circ-CDK8 enhanced the sensitivity of OSCC cells to erastin-induced ferroptosis by regulating SLC7A11 in vivo and in vitro. Therefore, induction of ferroptosis by controlling the circ-CDK8/miR-615-5p/ SLC7A11 regulatory axis might be a new therapeutic option for OSCC. In addition, with the wide application of cisplatin and iron death drugs in OSCC. It is more necessary to construct ferroptosis resistance cell lines and explore the regulation of circ-

FIGURE 6
Effect of interference with circ-CDK8 on tumorigenesis *in vivo*. **(A–C)** The tumor size and tumor weight were observed in two groups. **(D)** The expression of miR-615-5p. (E) The expression of SLC7A11 was observed between the two groups. Scar bar = 400 μm.

CDK8 on ferroptosis and biological behavior for it. Furthermore, interfering with the circ-CDK8 caused mitochondrial swelling and mitochondrial cristae reduction or disappearance in the OSCC cell line [\(Figure 4F\)](#page-7-0). Therefore, targeting mitochondriarelated ferroptosis could be a potential strategy for cancer therapy in the future.

In conclusion, our study first suggested that circ-CDK8 is overexpressed in oral squamous carcinoma cells and tissues. Furthermore, circ-CDK8 suppressed ferroptosis of OSCC cells through the miR-615-5p/SLC7A11 axis. These findings provided a novel insight into the molecular mechanisms of OSCC progression and presented a potential OSCC treatment strategy.

Data availability statement

The original contributions presented in the study are included in the article/[Supplementary Material,](#page-10-18) further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by the Ethics Committee of Affiliated Hospital of Qingdao University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. The animal study was approved by the Animal Care and Use Committee of the Affiliated Hospital of Qingdao University. The study was conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

KS: Conceptualization, Data curation, Formal Analysis, Methodology, Writing–original draft. LG: Conceptualization, Formal Analysis, Funding acquisition, Investigation, Writing–review and editing. SL: Formal Analysis, Methodology, Writing–review and editing. JZ: Formal Analysis, Funding acquisition, Methodology, Writing–review and editing. ZZ: Formal Analysis, Methodology, Writing–review and editing. KZ: Funding acquisition, Supervision, Writing–review and editing. WR: Conceptualization, Funding acquisition, Writing–review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study

References

Bose, R., and Ain, R. (2018). Regulation of transcription by circular RNAs. Adv. Exp. Med. Biol. 1087, 81-94. doi:10.1007/978-981-13-1426-1_

Chen, L. L. (2020). The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat. Rev. Mol. Cell Biol. 21, 475–490. doi:[10.1038/s41580-020-](https://doi.org/10.1038/s41580-020-0243-y) [0243-y](https://doi.org/10.1038/s41580-020-0243-y)

Chen, X., Kang, R., Kroemer, G., and Tang, D. (2021). Broadening horizons: the role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 18, 280–296. doi[:10.1038/s41571-020-](https://doi.org/10.1038/s41571-020-00462-0) [00462-0](https://doi.org/10.1038/s41571-020-00462-0)

Conrad, M., and Pratt, D. A. (2019). The chemical basis of ferroptosis. Nat. Chem. Biol. Dec 15, 1137–1147. doi[:10.1038/s41589-019-0408-1](https://doi.org/10.1038/s41589-019-0408-1)

Cui, Y., Liu, J., Liu, L., Ma, X., Gui, Y., Liu, H., et al. (2023). m(6)A-modified circFOXK2 targets GLUT1 to accelerate oral squamous cell carcinoma aerobic glycolysis. Cancer gene Ther. Jan. 30, 163–171. doi:[10.1038/s41417-022-00526-6](https://doi.org/10.1038/s41417-022-00526-6)

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072. doi[:10.1016/j.cell.2012.03.042](https://doi.org/10.1016/j.cell.2012.03.042)

Duprez, F., Berwouts, D., De Neve, W., Bonte, K., Boterberg, T., Deron, P., et al. (2017). Distant metastases in head and neck cancer. Head neck 39, 1733–1743. doi[:10.](https://doi.org/10.1002/hed.24687) [1002/hed.24687](https://doi.org/10.1002/hed.24687)

Gan, B. (2021). Mitochondrial regulation of ferroptosis. J. Cell Biol. 6, 220. doi[:10.](https://doi.org/10.1083/jcb.202105043) [1083/jcb.202105043](https://doi.org/10.1083/jcb.202105043)

Gao, L., Zhang, Q., Li, S., Zheng, J., Ren, W., and Zhi, K. (2022). Circ-PKD2 promotes Atg13-mediated autophagy by inhibiting miR-646 to increase the sensitivity of cisplatin in oral squamous cell carcinomas. Cell death Dis. 13, 192. doi[:10.1038/s41419-021-](https://doi.org/10.1038/s41419-021-04497-8) [04497-8](https://doi.org/10.1038/s41419-021-04497-8)

Gao, L., Zhao, C., Li, S., Dou, Z., Wang, Q., Liu, J., et al. (2019). circ-PKD2 inhibits carcinogenesis via the miR-204-3p/APC2 axis in oral squamous cell carcinoma. Mol. Carcinog. Oct. 58, 1783–1794. doi:[10.1002/mc.23065](https://doi.org/10.1002/mc.23065)

He, F., Zhang, P., Liu, J., Wang, R., Kaufman, R. J., Yaden, B. C., et al. (2023). ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stressrelated ferroptosis. J. hepatology 79, 362–377. doi:[10.1016/j.jhep.2023.03.016](https://doi.org/10.1016/j.jhep.2023.03.016)

Hong, X., Liu, N., Liang, Y., He, Q., Yang, X., Lei, Y., et al. (2020). Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1. Mol. cancer 19, 33. doi[:10.](https://doi.org/10.1186/s12943-020-01149-x) [1186/s12943-020-01149-x](https://doi.org/10.1186/s12943-020-01149-x)

was funded by Natural Science Foundation of Shandong Province (ZR2021MD065, ZR2021MH305, ZR2022MH223), TaiShan Scholars Foundation of Shandong Province (tsqn202306397).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full#supplementary-material) [full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fphar.2024.1432520/full#supplementary-material)

Lang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., et al. (2019). Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9, 1673–1685. doi:[10.1158/2159-](https://doi.org/10.1158/2159-8290.CD-19-0338) [8290.CD-19-0338](https://doi.org/10.1158/2159-8290.CD-19-0338)

Li, J., Cao, F., Yin, H. L., Huang, Z. J., Lin, Z. T., Mao, N., et al. (2020a). Ferroptosis: past, present and future. Cell Death Dis. Feb 3 (11), 88. doi[:10.1038/s41419-020-2298-2](https://doi.org/10.1038/s41419-020-2298-2)

Li, J., Sun, D., Pu, W., Wang, J., and Peng, Y. (2020b). Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends cancer. Apr 6, 319–336. doi[:10.](https://doi.org/10.1016/j.trecan.2020.01.012) [1016/j.trecan.2020.01.012](https://doi.org/10.1016/j.trecan.2020.01.012)

Li, X., Wang, C., Zhang, H., Li, Y., Hou, D., Liu, D., et al. (2023). circFNDC3B accelerates vasculature formation and metastasis in oral squamous cell carcinoma. Cancer Res. 83, 1459–1475. doi:[10.1158/0008-5472.CAN-22-2585](https://doi.org/10.1158/0008-5472.CAN-22-2585)

Liang, C., Zhang, X., Yang, M., and Dong, X. (2019). Recent progress in ferroptosis inducers for cancer therapy. Adv. Mater. Deerf. Beach, Fla. Dec 31, e1904197. doi[:10.](https://doi.org/10.1002/adma.201904197) [1002/adma.201904197](https://doi.org/10.1002/adma.201904197)

Lin, W., Wang, C., Liu, G., Bi, C., Wang, X., Zhou, Q., et al. (2020). SLC7A11/xCT in cancer: biological functions and therapeutic implications. Am. J. cancer Res. 10, 3106–3126.

Meric-Bernstam, F., Larkin, J., Tabernero, J., and Bonini, C. (2021). Enhancing antitumour efficacy with immunotherapy combinations. Lancet London, Engl. 397, 1010–1022. doi[:10.1016/S0140-6736\(20\)32598-8](https://doi.org/10.1016/S0140-6736(20)32598-8)

Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I., and Saba, N. F. (2021). Head and neck cancer. Lancet London, Engl. 398, 2289–2299. doi[:10.1016/S0140-6736\(21\)01550-6](https://doi.org/10.1016/S0140-6736(21)01550-6)

Ringash, J. (2015). Survivorship and quality of life in head and neck cancer. J. Clin. Oncol. official J. Am. Soc. Clin. Oncol. 33, 3322–3327. doi:[10.1200/JCO.](https://doi.org/10.1200/JCO.2015.61.4115) [2015.61.4115](https://doi.org/10.1200/JCO.2015.61.4115)

Shen, L., Zhang, J., Zheng, Z., Yang, F., Liu, S., Wu, Y., et al. (2022). PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder cancer. Int. J. Biol. Sci. 18, 5459–5474. doi:[10.7150/ijbs.74546](https://doi.org/10.7150/ijbs.74546)

Siegel, R. L., Miller, K. D., Wagle, N. S., and Jemal, A. (2023). Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48. doi[:10.3322/caac.21763](https://doi.org/10.3322/caac.21763)

Sun, K., Ren, W., Li, S., Zheng, J., Huang, Y., Zhi, K., et al. (2022a). MiR-34c-3p upregulates erastin-induced ferroptosis to inhibit proliferation in oral squamous cell carcinomas by targeting SLC7A11. Pathology, Res. Pract. 231, 153778. doi[:10.1016/j.prp.](https://doi.org/10.1016/j.prp.2022.153778) [2022.153778](https://doi.org/10.1016/j.prp.2022.153778)

Sun, S., Gao, T., Pang, B., Su, X., Guo, C., Zhang, R., et al. (2022b). RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting
SLC7A11 mRNA splicing in an m(6)A-dependent manner. *Cell death Dis.* 13, 73. doi[:10.1038/s41419-022-04524-2](https://doi.org/10.1038/s41419-022-04524-2)

Tan, S., Kong, Y., Xian, Y., Gao, P., Xu, Y., Wei, C., et al. (2022). The mechanisms of ferroptosis and the applications in tumor treatment: enemies or friends? Front. Mol. Biosci. 9, 938677. doi[:10.3389/fmolb.2022.938677](https://doi.org/10.3389/fmolb.2022.938677)

Wu, M., Kong, C., Cai, M., Huang, W., Chen, Y., Wang, B., et al. (2021a). Hsa_ circRNA_002144 promotes growth and metastasis of colorectal cancer through regulating miR-615-5p/LARP1/mTOR pathway. Carcinogenesis 42, 601–610. doi[:10.](https://doi.org/10.1093/carcin/bgaa140) [1093/carcin/bgaa140](https://doi.org/10.1093/carcin/bgaa140)

Wu, P., Li, C., Ye, D. M., Yu, K., Li, Y., Tang, H., et al. (2021b). Circular RNA circEPSTI1 accelerates cervical cancer progression via miR-375/409-3P/515-5p-SLC7A11 axis. Aging 13, 4663–4673. doi[:10.18632/aging.202518](https://doi.org/10.18632/aging.202518)

Xu, X., Li, Y., Wu, Y., Wang, M., Lu, Y., Fang, Z., et al. (2023). Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox Biol. 59, 102564. doi:[10.1016/j.redox.2022.102564](https://doi.org/10.1016/j.redox.2022.102564)

Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell. 16 (156), 317–331. doi:[10.1016/j.cell.2013.12.010](https://doi.org/10.1016/j.cell.2013.12.010)

Yang, W. S., and Stockwell, B. R. (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenicRAS-harboring cancer cells. Chem. Biol. 15, 234–245. doi:[10.1016/j.chembiol.](https://doi.org/10.1016/j.chembiol.2008.02.010) [2008.02.010](https://doi.org/10.1016/j.chembiol.2008.02.010)

Yuan, Y., Zhai, Y., Chen, J., Xu, X., and Wang, H. (2021). Kaempferol ameliorates oxygen-glucose deprivation/reoxygenation-induced neuronal ferroptosis by activating nrf2/slc7a11/GPX4 Axis. Biomolecules 22, 11. doi:[10.3390/biom11070923](https://doi.org/10.3390/biom11070923)

Zeng, L., Liu, Y. M., Yang, N., Zhang, T., and Xie, H. (2021). Hsa_circRNA_ 100146 promotes prostate cancer progression by upregulating TRIP13 via sponging miR-615-5p. Front. Mol. Biosci. 8, 693477. doi[:10.3389/fmolb.2021.693477](https://doi.org/10.3389/fmolb.2021.693477)

Zhang, J., Chen, S., Wei, S., Cheng, S., Shi, R., Zhao, R., et al. (2022).
CircRAPGEF5 interacts with RBFOX2 to confer ferroptosis resistance by
modulating alternative splicing of TFRC in endometrial cancer. Redox Biol. No 102493. doi[:10.1016/j.redox.2022.102493](https://doi.org/10.1016/j.redox.2022.102493)

Zhang, S., Chen, Z., Sun, J., An, N., and Xi, Q. (2023). Retraction Note: circRNA hsa_ circRNA_000069 promotes the proliferation, migration and invasion of cervical cancer through miR-873-5p/TUSC3 axis. Cancer Cell Int. 23, 115. doi[:10.1186/s12935-023-02964-0](https://doi.org/10.1186/s12935-023-02964-0)

Zhao, W., Cui, Y., Liu, L., Qi, X., Liu, J., Ma, S., et al. (2020). Splicing factor derived circular RNA circUHRF1 accelerates oral squamous cell carcinoma tumorigenesis via feedback loop. Cell death Differ. 27, 919–933. doi[:10.1038/s41418-019-0423-5](https://doi.org/10.1038/s41418-019-0423-5)

Zheng, R., Zhang, K., Tan, S., Gao, F., Zhang, Y., Xu, W., et al. (2022). Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3-eIF3h interaction. Mol. cancer 21, 49. doi:[10.1186/](https://doi.org/10.1186/s12943-021-01471-y) [s12943-021-01471-y](https://doi.org/10.1186/s12943-021-01471-y)